Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$2.02 - $5.04 $18 - $45
9 Added 0.03%
33,963 $72,000
Q2 2023

Aug 14, 2023

BUY
$4.76 - $6.59 $76 - $105
16 Added 0.05%
33,954 $161,000
Q1 2023

May 15, 2023

BUY
$4.24 - $11.12 $78,520 - $205,931
18,519 Added 120.11%
33,938 $193,000
Q4 2022

Feb 14, 2023

SELL
$9.86 - $23.83 $13.9 Million - $33.6 Million
-1,409,307 Reduced 98.92%
15,419 $155,000
Q3 2022

Nov 14, 2022

SELL
$21.04 - $36.06 $226,958 - $388,979
-10,787 Reduced 0.75%
1,424,726 $31.9 Million
Q2 2022

Aug 15, 2022

SELL
$17.78 - $42.39 $602,510 - $1.44 Million
-33,887 Reduced 2.31%
1,435,513 $35.6 Million
Q1 2022

May 16, 2022

SELL
$29.67 - $60.28 $2.17 Million - $4.41 Million
-73,204 Reduced 4.75%
1,469,400 $57 Million
Q4 2021

Feb 14, 2022

SELL
$47.84 - $64.34 $8.57 Million - $11.5 Million
-179,207 Reduced 10.41%
1,542,604 $90.3 Million
Q3 2021

Nov 16, 2021

SELL
$59.27 - $95.73 $6.17 Million - $9.97 Million
-104,173 Reduced 5.71%
1,721,811 $102 Million
Q2 2021

Aug 16, 2021

SELL
$67.25 - $92.52 $5.02 Million - $6.91 Million
-74,648 Reduced 3.93%
1,825,984 $158 Million
Q1 2021

May 17, 2021

SELL
$72.16 - $117.4 $46.5 Million - $75.7 Million
-644,936 Reduced 25.34%
1,900,632 $157 Million
Q4 2020

Feb 16, 2021

SELL
$38.09 - $100.95 $23.7 Million - $62.7 Million
-621,141 Reduced 19.61%
2,545,568 $231 Million
Q3 2020

Nov 16, 2020

SELL
$30.41 - $40.5 $15 Million - $20 Million
-492,685 Reduced 13.46%
3,166,709 $127 Million
Q2 2020

Aug 14, 2020

BUY
$20.21 - $35.23 $7.35 Million - $12.8 Million
363,775 Added 11.04%
3,659,394 $126 Million
Q1 2020

May 14, 2020

BUY
$17.28 - $31.88 $56.8 Million - $105 Million
3,285,567 Added 32685.7%
3,295,619 $73.2 Million
Q4 2019

Feb 18, 2020

BUY
$13.39 - $20.73 $134,596 - $208,377
10,052 New
10,052 $197,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $99.9M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.